Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Completed 2No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Solid Tumours 1Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × molibresib × Clear all
NCT02964507 2024-08-29

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

GlaxoSmithKline

Phase 1 Terminated
124 enrolled 23 charts
Breast

Breast Neoplasms, Neoplasms

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

GlaxoSmithKline

Phase 1 Terminated
73 enrolled 34 charts
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡